First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    ImmunoGen, Inc.

    IMRX · 2 developments mapped · last assessed 2026-08-27

    Market Ontology has mapped 2 macro, policy, and market developments to ImmunoGen, Inc. since 2026-08-27. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for IMRX yet, so no modelled value is shown. The IMRX valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run IMRX on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for IMRX. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Open question

      FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor

      Indirect competitive pressure or potential partnership opportunities in the broader oncology/targeted therapy space, depending on pipeline overlap or strategic shifts.

      · Moves competitive landscape for pipeline assets, market share assumptions for existing or future products

    What changed, by assumption

    Competitive landscape for pipeline assets
    • 2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitor
    Assumption not yet resolved
    • 2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinoma

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-08-27FDA Approves Revolution Medicines' RASONQUE as First Broad RAS Inhibitorwatch3-12m0.30
    2026-08-27FDA Approves Revolution Medicines RASONQUE for Metastatic Pancreatic Adenocarcinomawatch3-12m0.20